Avior Wealth Management LLC Buys 2,305 Shares of Danaher Co. (NYSE:DHR)

Avior Wealth Management LLC boosted its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 17.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,750 shares of the conglomerate's stock after purchasing an additional 2,305 shares during the period. Avior Wealth Management LLC's holdings in Danaher were worth $4,379,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of DHR. MQS Management LLC acquired a new position in Danaher during the first quarter valued at approximately $230,000. Crewe Advisors LLC purchased a new stake in Danaher during the 1st quarter worth $162,000. Payden & Rygel Investment Group acquired a new stake in Danaher in the 1st quarter valued at $250,000. Delap Wealth Advisory LLC purchased a new position in Danaher in the first quarter valued at about $348,000. Finally, CreativeOne Wealth LLC acquired a new position in shares of Danaher during the first quarter worth about $250,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Price Performance

DHR traded up $2.26 during midday trading on Wednesday, reaching $233.10. 2,642,129 shares of the company's stock were exchanged, compared to its average volume of 2,764,206. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The business has a 50-day simple moving average of $259.67 and a two-hundred day simple moving average of $260.13. The firm has a market capitalization of $168.36 billion, a price-to-earnings ratio of 44.48, a price-to-earnings-growth ratio of 4.24 and a beta of 0.85. Danaher Co. has a one year low of $213.61 and a one year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The business's revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.51 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's dividend payout ratio (DPR) is currently 20.61%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company's stock, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Barclays lowered their target price on Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Raymond James decreased their target price on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Royal Bank of Canada dropped their price target on shares of Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Finally, UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.